These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

656 related items for PubMed ID: 31905025

  • 1. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
    Gore E, Bigaeva E, Oldenburger A, Jansen YJM, Schuppan D, Boersema M, Rippmann JF, Broermann A, Olinga P.
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb 01; 318(2):G336-G351. PubMed ID: 31905025
    [Abstract] [Full Text] [Related]

  • 2. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS, Kristiansen MN, Hansen HH, Veidal SS, Rigbolt KT, Gillum MP, Jelsing J, Vrang N, Feigh M.
    World J Gastroenterol; 2018 Jan 14; 24(2):179-194. PubMed ID: 29375204
    [Abstract] [Full Text] [Related]

  • 3. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G, An P, Vaid KA, Nasser I, Huang P, Tan L, Zhao S, Schuppan D, Popov YV.
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan 01; 318(1):G174-G188. PubMed ID: 31630534
    [Abstract] [Full Text] [Related]

  • 4. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A, GOLDEN-505 Investigator Study Group.
    Gastroenterology; 2016 May 01; 150(5):1147-1159.e5. PubMed ID: 26874076
    [Abstract] [Full Text] [Related]

  • 5. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model.
    Nakanishi K, Kaji K, Kitade M, Kubo T, Furukawa M, Saikawa S, Shimozato N, Sato S, Seki K, Kawaratani H, Moriya K, Namisaki T, Yoshiji H.
    Int J Mol Sci; 2019 Jun 03; 20(11):. PubMed ID: 31163617
    [Abstract] [Full Text] [Related]

  • 6. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN, Veidal SS, Christoffersen C, Feigh M, Vrang N, Roth JD, Erickson M, Adorini L, Jelsing J.
    BMC Gastroenterol; 2019 Dec 28; 19(1):228. PubMed ID: 31883514
    [Abstract] [Full Text] [Related]

  • 7. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M, Bukong TN, Csak T, Saha B, Park JK, Ambade A, Kodys K, Szabo G.
    J Transl Med; 2015 Jun 16; 13():193. PubMed ID: 26077675
    [Abstract] [Full Text] [Related]

  • 8. Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice.
    Yang A, Yan X, Fan X, Shi Y, Huang T, Li W, Chen W, Jia J, You H.
    Hepatol Int; 2021 Oct 16; 15(5):1122-1135. PubMed ID: 34014450
    [Abstract] [Full Text] [Related]

  • 9. Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH.
    Boeckmans J, Buyl K, Natale A, Vandenbempt V, Branson S, De Boe V, Rogiers V, De Kock J, Rodrigues RM, Vanhaecke T.
    Pharmacol Res; 2019 Jun 16; 144():377-389. PubMed ID: 31028903
    [Abstract] [Full Text] [Related]

  • 10. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T, Briand F, Trenteseaux C, Merian J, Combes G, Najib S, Sulpice T, Martinez LO.
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct 01; 317(4):G508-G517. PubMed ID: 31460789
    [Abstract] [Full Text] [Related]

  • 11. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
    Magee N, Zou A, Ghosh P, Ahamed F, Delker D, Zhang Y.
    J Biol Chem; 2020 Jan 24; 295(4):994-1008. PubMed ID: 31831621
    [Abstract] [Full Text] [Related]

  • 12. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM, Verschuren L, Caspers MPM, Worms N, Menke AL, Princen HMG.
    Sci Rep; 2021 Mar 03; 11(1):5050. PubMed ID: 33658534
    [Abstract] [Full Text] [Related]

  • 13. Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis.
    Zou A, Magee N, Deng F, Lehn S, Zhong C, Zhang Y.
    J Biol Chem; 2018 Jun 01; 293(22):8656-8671. PubMed ID: 29666185
    [Abstract] [Full Text] [Related]

  • 14. A 3-week nonalcoholic steatohepatitis mouse model shows elafibranor benefits on hepatic inflammation and cell death.
    Briand F, Heymes C, Bonada L, Angles T, Charpentier J, Branchereau M, Brousseau E, Quinsat M, Fazilleau N, Burcelin R, Sulpice T.
    Clin Transl Sci; 2020 May 01; 13(3):529-538. PubMed ID: 31981449
    [Abstract] [Full Text] [Related]

  • 15. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH).
    Min-DeBartolo J, Schlerman F, Akare S, Wang J, McMahon J, Zhan Y, Syed J, He W, Zhang B, Martinez RV.
    PLoS One; 2019 May 01; 14(12):e0226854. PubMed ID: 31891606
    [Abstract] [Full Text] [Related]

  • 16. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
    Takatani N, Kono Y, Beppu F, Okamatsu-Ogura Y, Yamano Y, Miyashita K, Hosokawa M.
    Biochem Biophys Res Commun; 2020 Jul 23; 528(2):305-310. PubMed ID: 32475638
    [Abstract] [Full Text] [Related]

  • 17. Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis.
    Tølbøl KS, Stierstorfer B, Rippmann JF, Veidal SS, Rigbolt KTG, Schönberger T, Gillum MP, Hansen HH, Vrang N, Jelsing J, Feigh M, Broermann A.
    Dig Dis Sci; 2019 May 23; 64(5):1238-1256. PubMed ID: 30511198
    [Abstract] [Full Text] [Related]

  • 18. Overactivation of intestinal sterol response element-binding protein 2 promotes diet-induced nonalcoholic steatohepatitis.
    Malhotra P, Aloman C, Ankireddy A, Khadra H, Ooka K, Gill RK, Saksena S, Dudeja PK, Alrefai WA.
    Am J Physiol Gastrointest Liver Physiol; 2017 Nov 01; 313(5):G376-G385. PubMed ID: 28774869
    [Abstract] [Full Text] [Related]

  • 19. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW, Hsu YC, Lee TF, Lin Y, Chiu YT, Yang KC, Wu JC, Huang YT.
    BMC Gastroenterol; 2015 Feb 15; 15():22. PubMed ID: 25886887
    [Abstract] [Full Text] [Related]

  • 20. Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery.
    Boeckmans J, Gatzios A, Heymans A, Rombaut M, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM.
    Cells; 2022 Mar 04; 11(5):. PubMed ID: 35269515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.